Ondansetron Baxter (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the chemoreceptor trigger zone of the brain and on vagal nerves of the gastrointestinal tract. This inhibition stops serotonin from activating the vomiting reflex, thereby reducing nausea and vomiting.

The dose of ondansetron is set by the prescribing clinician based on the specific indication, patient age, weight, renal and hepatic function, and the emetogenic potential of the chemotherapy or procedure. Dosage recommendations are provided in the product labeling and must be individualized.

Ondansetron is classified as a pregnancy category B drug, indicating no proven risk in animal studies but limited human data. It should be used during pregnancy only if the potential benefit justifies the risk. Small amounts are excreted in breast milk; breastfeeding mothers should discuss use with their healthcare provider.

To order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which is highly effective for chemotherapy‑ and radiation‑induced nausea. Compared with dopamine antagonists (e.g., metoclopramide) it has fewer extrapyramidal side effects, and unlike antihistamines it does not cause sedation. Choice depends on the clinical scenario and patient tolerance.

Ondansetron tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and light. Keep the product out of reach of children. No special refrigeration is required for the tablet form.

Ondansetron is administered orally as a tablet, typically with or without food, according to the prescriber’s instructions. In some clinical settings, intravenous or oral solution forms are used, but the tablet formulation is intended for oral use.

The most serious risks include QT interval prolongation that can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic agents. Patients with known cardiac conduction disorders or electrolyte imbalances should be monitored closely.

Ondansetron should be avoided in individuals with known hypersensitivity to the drug or other 5‑HT3 antagonists. Patients with congenital long QT syndrome, uncontrolled electrolyte disturbances, or those taking other QT‑prolonging medications should not use it without careful medical supervision.